These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19759548)

  • 1. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.
    Jones CL; Wain EM; Chu CC; Tosi I; Foster R; McKenzie RC; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2010 Apr; 130(4):1116-25. PubMed ID: 19759548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
    Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.
    Wong HK; Gibson H; Hake T; Geyer S; Frederickson J; Marcucci G; Caligiuri MA; Porcu P; Mishra A
    J Invest Dermatol; 2015 Aug; 135(8):2084-2092. PubMed ID: 25806852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD164 identifies CD4
    Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
    Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.
    Ni X; Zhang C; Talpur R; Duvic M
    J Invest Dermatol; 2005 Apr; 124(4):741-50. PubMed ID: 15816832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma.
    Petak I; Danam RP; Tillman DM; Vernes R; Howell SR; Berczi L; Kopper L; Brent TP; Houghton JA
    Cell Death Differ; 2003 Feb; 10(2):211-7. PubMed ID: 12700649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
    Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
    Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
    Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
    Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma.
    Butler LM; Dobrovic A; Bianco T; Cowled PA
    Br J Cancer; 2000 Jan; 82(1):131-5. PubMed ID: 10638979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.
    van Doorn R; Slieker RC; Boonk SE; Zoutman WH; Goeman JJ; Bagot M; Michel L; Tensen CP; Willemze R; Heijmans BT; Vermeer MH
    J Invest Dermatol; 2016 Sep; 136(9):1876-1884. PubMed ID: 27113428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
    Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
    Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
    Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
    J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
    van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Patterns of Methylation in Sézary Syndrome Provide Insight into the Role of Epigenetics in Cutaneous T-Cell Lymphoma.
    Whittaker S
    J Invest Dermatol; 2016 Sep; 136(9):1753-1754. PubMed ID: 27542296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of T-plastin in Sezary cells.
    Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
    Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of PTEN status in Sezary syndrome.
    Cristofoletti C; Picchio MC; Lazzeri C; Tocco V; Pagani E; Bresin A; Mancini B; Passarelli F; Facchiano A; Scala E; Lombardo GA; Cantonetti M; Caprini E; Russo G; Narducci MG
    Blood; 2013 Nov; 122(20):3511-20. PubMed ID: 24062018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
    J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.